Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | TRPM5 | Q9NZQ8 | 4/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29879831 | 1.00 | LRRK2 (0.39) | LRRK2MAP4K1ABL1TRPM5IKBKB | |
| SCHEMBL29136745 | 0.90 | KDM4E (0.42) | LRRK2MAP4K1TRPM5LMNA | |
| SCHEMBL29136748 | 0.90 | KDM4E (0.42) | LRRK2MAP4K1TRPM5LMNA | |
| SCHEMBL24738299 | 0.90 | KDM4E (0.42) | LRRK2MAP4K1TRPM5LMNA | |
| SCHEMBL29136885 | 0.88 | LRRK2 (0.39) | LRRK2MAP4K1ABL1TRPM5LMNA | |
| SCHEMBL24738275 | 0.88 | LRRK2 (0.39) | LRRK2MAP4K1ABL1TRPM5LMNA | |
| SCHEMBL29136884 | 0.88 | LRRK2 (0.39) | LRRK2MAP4K1ABL1TRPM5LMNA | |
| SCHEMBL29136881 | 0.87 | KLKB1 (0.42) | LRRK2 | |
| SCHEMBL29879679 | 0.87 | KLKB1 (0.42) | LRRK2 | |
| SCHEMBL29136883 | 0.87 | KLKB1 (0.42) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | LRRK2 1555/4885MAP4K1 639/4885ABL1 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.